Medical Care
Squamous Non-Small Cell Lung Cancer Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 11, 24
- ID: 546900
- Pages: 128
- Figures: 205
- Views: 1
The global market for Squamous Non-Small Cell Lung Cancer Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Squamous Non-Small Cell Lung Cancer Therapeutics by region & country, by Type, and by Application.
The Squamous Non-Small Cell Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Squamous Non-Small Cell Lung Cancer Therapeutics.
Market Segmentation
By Company
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Segment by Type:
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Segment by Application
Research Center
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Squamous Non-Small Cell Lung Cancer Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Squamous Non-Small Cell Lung Cancer Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Squamous Non-Small Cell Lung Cancer Therapeutics by region & country, by Type, and by Application.
The Squamous Non-Small Cell Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Squamous Non-Small Cell Lung Cancer Therapeutics.
Market Segmentation
By Company
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Segment by Type:
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Segment by Application
Research Center
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Squamous Non-Small Cell Lung Cancer Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Squamous Non-Small Cell Lung Cancer Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast
1.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends & Drivers
1.3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
1.3.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers & Opportunity
1.3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
1.3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Players Revenue Ranking (2023)
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Squamous Non-Small Cell Lung Cancer Therapeutics
2.6 Squamous Non-Small Cell Lung Cancer Therapeutics Market Competitive Analysis
2.6.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 BMS-906024
3.1.2 Buparlisib Hydrochloride
3.1.3 FP-1039
3.1.4 Ipilimumab
3.1.5 JNJ-42756493
3.1.6 Lenvatinib
3.1.7 Others
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type
3.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Research Center
4.1.2 Hospital
4.1.3 Clinic
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application
4.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region
5.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.2.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.5.2 South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value
6.3 United States
6.3.1 United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.3.2 United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.4.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.5.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.6.2 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.9.2 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Ascenta Therapeutics, Inc.
7.1.1 Ascenta Therapeutics, Inc. Profile
7.1.2 Ascenta Therapeutics, Inc. Main Business
7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 Ascenta Therapeutics, Inc. Recent Developments
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Profile
7.2.2 AstraZeneca Plc Main Business
7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 AstraZeneca Plc Recent Developments
7.3 AVEO Pharmaceuticals, Inc.
7.3.1 AVEO Pharmaceuticals, Inc. Profile
7.3.2 AVEO Pharmaceuticals, Inc. Main Business
7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Bayer AG Recent Developments
7.4 Bayer AG
7.4.1 Bayer AG Profile
7.4.2 Bayer AG Main Business
7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Bayer AG Recent Developments
7.5 BIND Therapeutics, Inc.
7.5.1 BIND Therapeutics, Inc. Profile
7.5.2 BIND Therapeutics, Inc. Main Business
7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 BIND Therapeutics, Inc. Recent Developments
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Profile
7.6.2 Boehringer Ingelheim GmbH Main Business
7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Boehringer Ingelheim GmbH Recent Developments
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Profile
7.7.2 Bristol-Myers Squibb Company Main Business
7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Bristol-Myers Squibb Company Recent Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Profile
7.8.2 Eli Lilly and Company Main Business
7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Eli Lilly and Company Recent Developments
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Profile
7.9.2 F. Hoffmann-La Roche Ltd. Main Business
7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.10 Five Prime Therapeutics, Inc.
7.10.1 Five Prime Therapeutics, Inc. Profile
7.10.2 Five Prime Therapeutics, Inc. Main Business
7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Five Prime Therapeutics, Inc. Recent Developments
7.11 Genentech, Inc.
7.11.1 Genentech, Inc. Profile
7.11.2 Genentech, Inc. Main Business
7.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 Genentech, Inc. Recent Developments
7.12 Incyte Corporation
7.12.1 Incyte Corporation Profile
7.12.2 Incyte Corporation Main Business
7.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.12.5 Incyte Corporation Recent Developments
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Profile
7.13.2 Johnson & Johnson Main Business
7.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.13.5 Johnson & Johnson Recent Developments
7.14 MacroGenics, Inc.
7.14.1 MacroGenics, Inc. Profile
7.14.2 MacroGenics, Inc. Main Business
7.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.14.5 MacroGenics, Inc. Recent Developments
7.15 Novartis AG
7.15.1 Novartis AG Profile
7.15.2 Novartis AG Main Business
7.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.15.5 Novartis AG Recent Developments
7.16 Oncogenex Pharmaceuticals, Inc.
7.16.1 Oncogenex Pharmaceuticals, Inc. Profile
7.16.2 Oncogenex Pharmaceuticals, Inc. Main Business
7.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.16.5 Oncogenex Pharmaceuticals, Inc. Recent Developments
7.17 PsiOxus Therapeutics Limited
7.17.1 PsiOxus Therapeutics Limited Profile
7.17.2 PsiOxus Therapeutics Limited Main Business
7.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.17.5 PsiOxus Therapeutics Limited Recent Developments
8 Industry Chain Analysis
8.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industrial Chain
8.2 Squamous Non-Small Cell Lung Cancer Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Squamous Non-Small Cell Lung Cancer Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Squamous Non-Small Cell Lung Cancer Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast
1.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends & Drivers
1.3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
1.3.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers & Opportunity
1.3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
1.3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Players Revenue Ranking (2023)
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Squamous Non-Small Cell Lung Cancer Therapeutics
2.6 Squamous Non-Small Cell Lung Cancer Therapeutics Market Competitive Analysis
2.6.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 BMS-906024
3.1.2 Buparlisib Hydrochloride
3.1.3 FP-1039
3.1.4 Ipilimumab
3.1.5 JNJ-42756493
3.1.6 Lenvatinib
3.1.7 Others
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type
3.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Research Center
4.1.2 Hospital
4.1.3 Clinic
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application
4.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region
5.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.2.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.5.2 South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value
6.3 United States
6.3.1 United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.3.2 United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.4.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.5.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.6.2 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019-2030
6.9.2 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Ascenta Therapeutics, Inc.
7.1.1 Ascenta Therapeutics, Inc. Profile
7.1.2 Ascenta Therapeutics, Inc. Main Business
7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 Ascenta Therapeutics, Inc. Recent Developments
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Profile
7.2.2 AstraZeneca Plc Main Business
7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 AstraZeneca Plc Recent Developments
7.3 AVEO Pharmaceuticals, Inc.
7.3.1 AVEO Pharmaceuticals, Inc. Profile
7.3.2 AVEO Pharmaceuticals, Inc. Main Business
7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Bayer AG Recent Developments
7.4 Bayer AG
7.4.1 Bayer AG Profile
7.4.2 Bayer AG Main Business
7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Bayer AG Recent Developments
7.5 BIND Therapeutics, Inc.
7.5.1 BIND Therapeutics, Inc. Profile
7.5.2 BIND Therapeutics, Inc. Main Business
7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 BIND Therapeutics, Inc. Recent Developments
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Profile
7.6.2 Boehringer Ingelheim GmbH Main Business
7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Boehringer Ingelheim GmbH Recent Developments
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Profile
7.7.2 Bristol-Myers Squibb Company Main Business
7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Bristol-Myers Squibb Company Recent Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Profile
7.8.2 Eli Lilly and Company Main Business
7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Eli Lilly and Company Recent Developments
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Profile
7.9.2 F. Hoffmann-La Roche Ltd. Main Business
7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.10 Five Prime Therapeutics, Inc.
7.10.1 Five Prime Therapeutics, Inc. Profile
7.10.2 Five Prime Therapeutics, Inc. Main Business
7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Five Prime Therapeutics, Inc. Recent Developments
7.11 Genentech, Inc.
7.11.1 Genentech, Inc. Profile
7.11.2 Genentech, Inc. Main Business
7.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 Genentech, Inc. Recent Developments
7.12 Incyte Corporation
7.12.1 Incyte Corporation Profile
7.12.2 Incyte Corporation Main Business
7.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.12.5 Incyte Corporation Recent Developments
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Profile
7.13.2 Johnson & Johnson Main Business
7.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.13.5 Johnson & Johnson Recent Developments
7.14 MacroGenics, Inc.
7.14.1 MacroGenics, Inc. Profile
7.14.2 MacroGenics, Inc. Main Business
7.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.14.5 MacroGenics, Inc. Recent Developments
7.15 Novartis AG
7.15.1 Novartis AG Profile
7.15.2 Novartis AG Main Business
7.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.15.5 Novartis AG Recent Developments
7.16 Oncogenex Pharmaceuticals, Inc.
7.16.1 Oncogenex Pharmaceuticals, Inc. Profile
7.16.2 Oncogenex Pharmaceuticals, Inc. Main Business
7.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.16.5 Oncogenex Pharmaceuticals, Inc. Recent Developments
7.17 PsiOxus Therapeutics Limited
7.17.1 PsiOxus Therapeutics Limited Profile
7.17.2 PsiOxus Therapeutics Limited Main Business
7.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
7.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.17.5 PsiOxus Therapeutics Limited Recent Developments
8 Industry Chain Analysis
8.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industrial Chain
8.2 Squamous Non-Small Cell Lung Cancer Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Squamous Non-Small Cell Lung Cancer Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Squamous Non-Small Cell Lung Cancer Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Table 2. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers & Opportunity
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 4. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Table 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Squamous Non-Small Cell Lung Cancer Therapeutics
Table 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. Ascenta Therapeutics, Inc. Basic Information List
Table 32. Ascenta Therapeutics, Inc. Description and Business Overview
Table 33. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Ascenta Therapeutics, Inc. (2019-2024)
Table 35. Ascenta Therapeutics, Inc. Recent Developments
Table 36. AstraZeneca Plc Basic Information List
Table 37. AstraZeneca Plc Description and Business Overview
Table 38. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of AstraZeneca Plc (2019-2024)
Table 40. AstraZeneca Plc Recent Developments
Table 41. AVEO Pharmaceuticals, Inc. Basic Information List
Table 42. AVEO Pharmaceuticals, Inc. Description and Business Overview
Table 43. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of AVEO Pharmaceuticals, Inc. (2019-2024)
Table 45. AVEO Pharmaceuticals, Inc. Recent Developments
Table 46. Bayer AG Basic Information List
Table 47. Bayer AG Description and Business Overview
Table 48. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Bayer AG (2019-2024)
Table 50. Bayer AG Recent Developments
Table 51. BIND Therapeutics, Inc. Basic Information List
Table 52. BIND Therapeutics, Inc. Description and Business Overview
Table 53. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of BIND Therapeutics, Inc. (2019-2024)
Table 55. BIND Therapeutics, Inc. Recent Developments
Table 56. Boehringer Ingelheim GmbH Basic Information List
Table 57. Boehringer Ingelheim GmbH Description and Business Overview
Table 58. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Boehringer Ingelheim GmbH (2019-2024)
Table 60. Boehringer Ingelheim GmbH Recent Developments
Table 61. Bristol-Myers Squibb Company Basic Information List
Table 62. Bristol-Myers Squibb Company Description and Business Overview
Table 63. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Bristol-Myers Squibb Company (2019-2024)
Table 65. Bristol-Myers Squibb Company Recent Developments
Table 66. Eli Lilly and Company Basic Information List
Table 67. Eli Lilly and Company Description and Business Overview
Table 68. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Eli Lilly and Company (2019-2024)
Table 70. Eli Lilly and Company Recent Developments
Table 71. F. Hoffmann-La Roche Ltd. Basic Information List
Table 72. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 73. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of F. Hoffmann-La Roche Ltd. (2019-2024)
Table 75. F. Hoffmann-La Roche Ltd. Recent Developments
Table 76. Five Prime Therapeutics, Inc. Basic Information List
Table 77. Five Prime Therapeutics, Inc. Description and Business Overview
Table 78. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Five Prime Therapeutics, Inc. (2019-2024)
Table 80. Five Prime Therapeutics, Inc. Recent Developments
Table 81. Genentech, Inc. Basic Information List
Table 82. Genentech, Inc. Description and Business Overview
Table 83. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 84. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Genentech, Inc. (2019-2024)
Table 85. Genentech, Inc. Recent Developments
Table 86. Incyte Corporation Basic Information List
Table 87. Incyte Corporation Description and Business Overview
Table 88. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 89. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Incyte Corporation (2019-2024)
Table 90. Incyte Corporation Recent Developments
Table 91. Johnson & Johnson Basic Information List
Table 92. Johnson & Johnson Description and Business Overview
Table 93. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 94. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Johnson & Johnson (2019-2024)
Table 95. Johnson & Johnson Recent Developments
Table 96. MacroGenics, Inc. Basic Information List
Table 97. MacroGenics, Inc. Description and Business Overview
Table 98. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 99. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of MacroGenics, Inc. (2019-2024)
Table 100. MacroGenics, Inc. Recent Developments
Table 101. Novartis AG Basic Information List
Table 102. Novartis AG Description and Business Overview
Table 103. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 104. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Novartis AG (2019-2024)
Table 105. Novartis AG Recent Developments
Table 106. Oncogenex Pharmaceuticals, Inc. Basic Information List
Table 107. Oncogenex Pharmaceuticals, Inc. Description and Business Overview
Table 108. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 109. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Oncogenex Pharmaceuticals, Inc. (2019-2024)
Table 110. Oncogenex Pharmaceuticals, Inc. Recent Developments
Table 111. PsiOxus Therapeutics Limited Basic Information List
Table 112. PsiOxus Therapeutics Limited Description and Business Overview
Table 113. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 114. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of PsiOxus Therapeutics Limited (2019-2024)
Table 115. PsiOxus Therapeutics Limited Recent Developments
Table 116. Key Raw Materials Lists
Table 117. Raw Materials Key Suppliers Lists
Table 118. Squamous Non-Small Cell Lung Cancer Therapeutics Downstream Customers
Table 119. Squamous Non-Small Cell Lung Cancer Therapeutics Distributors List
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
Table 123. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Product Picture
Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
Figure 7. Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. BMS-906024 Picture
Figure 9. Buparlisib Hydrochloride Picture
Figure 10. FP-1039 Picture
Figure 11. Ipilimumab Picture
Figure 12. JNJ-42756493 Picture
Figure 13. Lenvatinib Picture
Figure 14. Others Picture
Figure 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 17. Product Picture of Research Center
Figure 18. Product Picture of Hospital
Figure 19. Product Picture of Clinic
Figure 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 22. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 24. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 26. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 28. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 29. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 32. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (%), (2019-2030)
Figure 33. United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 34. United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 35. United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 36. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 37. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 38. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 39. China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 40. China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 41. China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 42. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 43. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 44. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 45. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 46. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 47. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 48. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 49. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 50. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 51. India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 52. India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 53. India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 54. Squamous Non-Small Cell Lung Cancer Therapeutics Industrial Chain
Figure 55. Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Table 2. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers & Opportunity
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 4. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Table 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Squamous Non-Small Cell Lung Cancer Therapeutics
Table 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. Ascenta Therapeutics, Inc. Basic Information List
Table 32. Ascenta Therapeutics, Inc. Description and Business Overview
Table 33. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Ascenta Therapeutics, Inc. (2019-2024)
Table 35. Ascenta Therapeutics, Inc. Recent Developments
Table 36. AstraZeneca Plc Basic Information List
Table 37. AstraZeneca Plc Description and Business Overview
Table 38. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of AstraZeneca Plc (2019-2024)
Table 40. AstraZeneca Plc Recent Developments
Table 41. AVEO Pharmaceuticals, Inc. Basic Information List
Table 42. AVEO Pharmaceuticals, Inc. Description and Business Overview
Table 43. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of AVEO Pharmaceuticals, Inc. (2019-2024)
Table 45. AVEO Pharmaceuticals, Inc. Recent Developments
Table 46. Bayer AG Basic Information List
Table 47. Bayer AG Description and Business Overview
Table 48. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Bayer AG (2019-2024)
Table 50. Bayer AG Recent Developments
Table 51. BIND Therapeutics, Inc. Basic Information List
Table 52. BIND Therapeutics, Inc. Description and Business Overview
Table 53. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of BIND Therapeutics, Inc. (2019-2024)
Table 55. BIND Therapeutics, Inc. Recent Developments
Table 56. Boehringer Ingelheim GmbH Basic Information List
Table 57. Boehringer Ingelheim GmbH Description and Business Overview
Table 58. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Boehringer Ingelheim GmbH (2019-2024)
Table 60. Boehringer Ingelheim GmbH Recent Developments
Table 61. Bristol-Myers Squibb Company Basic Information List
Table 62. Bristol-Myers Squibb Company Description and Business Overview
Table 63. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Bristol-Myers Squibb Company (2019-2024)
Table 65. Bristol-Myers Squibb Company Recent Developments
Table 66. Eli Lilly and Company Basic Information List
Table 67. Eli Lilly and Company Description and Business Overview
Table 68. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Eli Lilly and Company (2019-2024)
Table 70. Eli Lilly and Company Recent Developments
Table 71. F. Hoffmann-La Roche Ltd. Basic Information List
Table 72. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 73. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of F. Hoffmann-La Roche Ltd. (2019-2024)
Table 75. F. Hoffmann-La Roche Ltd. Recent Developments
Table 76. Five Prime Therapeutics, Inc. Basic Information List
Table 77. Five Prime Therapeutics, Inc. Description and Business Overview
Table 78. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Five Prime Therapeutics, Inc. (2019-2024)
Table 80. Five Prime Therapeutics, Inc. Recent Developments
Table 81. Genentech, Inc. Basic Information List
Table 82. Genentech, Inc. Description and Business Overview
Table 83. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 84. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Genentech, Inc. (2019-2024)
Table 85. Genentech, Inc. Recent Developments
Table 86. Incyte Corporation Basic Information List
Table 87. Incyte Corporation Description and Business Overview
Table 88. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 89. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Incyte Corporation (2019-2024)
Table 90. Incyte Corporation Recent Developments
Table 91. Johnson & Johnson Basic Information List
Table 92. Johnson & Johnson Description and Business Overview
Table 93. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 94. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Johnson & Johnson (2019-2024)
Table 95. Johnson & Johnson Recent Developments
Table 96. MacroGenics, Inc. Basic Information List
Table 97. MacroGenics, Inc. Description and Business Overview
Table 98. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 99. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of MacroGenics, Inc. (2019-2024)
Table 100. MacroGenics, Inc. Recent Developments
Table 101. Novartis AG Basic Information List
Table 102. Novartis AG Description and Business Overview
Table 103. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 104. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Novartis AG (2019-2024)
Table 105. Novartis AG Recent Developments
Table 106. Oncogenex Pharmaceuticals, Inc. Basic Information List
Table 107. Oncogenex Pharmaceuticals, Inc. Description and Business Overview
Table 108. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 109. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of Oncogenex Pharmaceuticals, Inc. (2019-2024)
Table 110. Oncogenex Pharmaceuticals, Inc. Recent Developments
Table 111. PsiOxus Therapeutics Limited Basic Information List
Table 112. PsiOxus Therapeutics Limited Description and Business Overview
Table 113. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
Table 114. Revenue (US$ Million) in Squamous Non-Small Cell Lung Cancer Therapeutics Business of PsiOxus Therapeutics Limited (2019-2024)
Table 115. PsiOxus Therapeutics Limited Recent Developments
Table 116. Key Raw Materials Lists
Table 117. Raw Materials Key Suppliers Lists
Table 118. Squamous Non-Small Cell Lung Cancer Therapeutics Downstream Customers
Table 119. Squamous Non-Small Cell Lung Cancer Therapeutics Distributors List
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
Table 123. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Product Picture
Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
Figure 7. Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. BMS-906024 Picture
Figure 9. Buparlisib Hydrochloride Picture
Figure 10. FP-1039 Picture
Figure 11. Ipilimumab Picture
Figure 12. JNJ-42756493 Picture
Figure 13. Lenvatinib Picture
Figure 14. Others Picture
Figure 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 17. Product Picture of Research Center
Figure 18. Product Picture of Hospital
Figure 19. Product Picture of Clinic
Figure 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 22. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 24. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 26. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 28. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 29. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 32. Key Countries/Regions Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value (%), (2019-2030)
Figure 33. United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 34. United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 35. United States Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 36. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 37. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 38. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 39. China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 40. China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 41. China Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 42. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 43. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 44. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 45. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 46. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 47. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 48. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 49. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 50. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 51. India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 52. India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 53. India Squamous Non-Small Cell Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 54. Squamous Non-Small Cell Lung Cancer Therapeutics Industrial Chain
Figure 55. Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232